Apr 8 |
RedHill GAAP EPS of $0.01, revenue of $6.53M
|
Apr 8 |
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
|
Mar 5 |
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
|
Feb 20 |
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
|
Feb 9 |
RedHill Biopharma files to sell 10.6M ADS for holders
|
Jan 26 |
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
|
Jan 25 |
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
|
Dec 20 |
RedHill shares rally 20% on positive data for two antiviral drugs
|
Dec 20 |
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
|
Dec 12 |
RedHill Biopharma regains compliance with Nasdaq listing rule
|